A comprehensive molecular analysis of the second-most-common type of kidney cancer sets the stage for more precise diagnoses and more tailored treatments.
More than 60,000 people are diagnosed with kidney cancer in the United States every year. About 20 percent of these patients have papillary renal cell carcinoma, the second-most-common type of kidney cancer. Currently, papillary renal cell carcinomas are classified into one of two subtypes based on their appearance under a microscope. Even within the same subtype, some of these cancers are much more aggressive than others, and clinicians need better tools for differentiating between these tumors and identifying the best treatments for individual patients.
Marston Linehan, M.D., Chief of CCR’s Urologic Oncology Branch, teamed up with his colleagues Kimryn Rathmell, M.D, Ph.D., from Vanderbilt University and Paul Spellman, Ph.D., from Oregon Health and Science University and The Cancer Genome Atlas (TCGA) Research Network, a collaborative effort supported and managed by NCI and the National Human Genome Research Institute, to search for clues to help researchers devise better ways to diagnose and treat these tumors. Their comprehensive molecular analysis of 161 papillary renal cell carcinoma tumors, reported in the New England Journal of Medicine, identified genetic pathways that are commonly disrupted in subgroups of papillary renal cell carcinomas and suggested strategies for developing targeted therapies.
The analysis, which compared the genetic sequences of tumors to those of healthy kidney tissue, analyzed patternsof gene activity and surveyed the proteins and RNA molecules present in tumor cells. It confirmed that the two clinical subtypes of papillary renal cell carcinoma are genetically distinct.
Type 1 tumors, the researchers found, may be characterized by disruptions to a signaling pathway involving the MET gene. Patients with these tumors might benefit from drugs that target this pathway. Changes to MET signaling are known to drive the growth and spread of cancer cells and spur the development of blood vessels that supply tumors with oxygen. Several inhibitors of the MET pathway are already being evaluated in clinical trials for the treatment of various cancers, including papillary renal cell carcinoma.
Among the Type 2 tumors, the researchers identified a subgroup characterized by high levels of DNA methylation, a chemical modification that dampens the activity of affected genes. Tumors in this subgroup were associated with the least-favorable clinical outcomes. Loss of the tumor suppressor gene CDKN2A, which affected about 25 percent of Type 2 tumors, was also associated with a poor prognosis.
These findings are the latest chapter of work completed by CCR scientists that have led to a more sophisticated system of classifying kidney cancers and allowed patients and their doctors to make more informed treatment decisions.
Linehan WM, et al. N Engl J Med. 2016 Jan 14;374(2):135-45.